


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:49:06Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405396" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405396</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Rheumatol Int</journal-id><journal-id journal-id-type="iso-abbrev">Rheumatol Int</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Rheumatology International</journal-title></journal-title-group><issn pub-type="ppub">0172-8172</issn><issn pub-type="epub">1437-160X</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405396</article-id><article-id pub-id-type="pmcid-ver">PMC12405396.1</article-id><article-id pub-id-type="pmcaid">12405396</article-id><article-id pub-id-type="pmcaiid">12405396</article-id><article-id pub-id-type="pmid">40892253</article-id><article-id pub-id-type="doi">10.1007/s00296-025-05966-5</article-id><article-id pub-id-type="publisher-id">5966</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Epidemiology of RMDs</subject></subj-group></article-categories><title-group><article-title>Psoriatic arthritis incidence and prevalence trajectory in Poland&#8212;public-payer, national-level, long-term data</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7857-347X</contrib-id><name name-style="western"><surname>Krajewska-W&#322;odarczyk</surname><given-names initials="M">Magdalena</given-names></name><address><email>magdalenakw@op.pl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4957-6620</contrib-id><name name-style="western"><surname>Szel&#261;g</surname><given-names initials="M">Mateusz</given-names></name><address><email>mszelag@mz.gov.pl</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3999-8093</contrib-id><name name-style="western"><surname>Batko</surname><given-names initials="B">Bogdan</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3939-7194</contrib-id><name name-style="western"><surname>Stajszczyk</surname><given-names initials="M">Marcin</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0000-5065-2582</contrib-id><name name-style="western"><surname>Orlea&#324;ski</surname><given-names initials="M">Micha&#322;</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2902-8029</contrib-id><name name-style="western"><surname>Podw&#243;jcic</surname><given-names initials="K">Krzysztof</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0001-3890-9370</contrib-id><name name-style="western"><surname>Sowi&#324;ski</surname><given-names initials="J">Jakub</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0000-6121-4190</contrib-id><name name-style="western"><surname>&#346;widerek</surname><given-names initials="M">Maria</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7681-4367</contrib-id><name name-style="western"><surname>Brzosko</surname><given-names initials="M">Marek</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0003-4340-6991</contrib-id><name name-style="western"><surname>&#346;miglewska</surname><given-names initials="A">Agata</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9622-1830</contrib-id><name name-style="western"><surname>Kwiatkowska</surname><given-names initials="B">Brygida</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9581-0601</contrib-id><name name-style="western"><surname>&#379;uber</surname><given-names initials="Z">Zbigniew</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05s4feg49</institution-id><institution-id institution-id-type="GRID">grid.412607.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2149 6795</institution-id><institution>Clinic of Rheumatology, School of Medicine, Collegium Medicum, </institution><institution>University of Warmia and Mazury, </institution></institution-wrap>Olsztyn, Poland </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02ksnyp08</institution-id><institution-id institution-id-type="GRID">grid.490662.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 1087 1211</institution-id><institution>Department of Analysis and Strategy, </institution><institution>Ministry of Health, </institution></institution-wrap>Warsaw, Poland </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03m9nwf24</institution-id><institution-id institution-id-type="GRID">grid.445217.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0724 0400</institution-id><institution>Department of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, </institution><institution>Andrzej Frycz Modrzewski University, </institution></institution-wrap>Krakow, Poland </aff><aff id="Aff4"><label>4</label>Department of Rheumatology and Autoimmune Diseases, Silesian Center for Rheumatology, Ustro&#324;, Poland </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01smd1r12</institution-id><institution-id institution-id-type="GRID">grid.493357.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2159 5515</institution-id><institution>Institute of Labour and Social Studies, </institution></institution-wrap>Warsaw, Poland </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01v1rak05</institution-id><institution-id institution-id-type="GRID">grid.107950.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 1411 4349</institution-id><institution>Department of Rheumatology, Internal Diseases, Geriatrics and Clinical Immunology, Faculty of Medicine and Dentistry, </institution><institution>Pomeranian Medical University, </institution></institution-wrap>Szczecin, Poland </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03gz68w66</institution-id><institution-id institution-id-type="GRID">grid.460480.e</institution-id><institution>Clinic of Early Arthritis, </institution><institution>National Institute of Geriatrics, Rheumatology and Rehabilitation, </institution></institution-wrap>Warsaw, Poland </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03m9nwf24</institution-id><institution-id institution-id-type="GRID">grid.445217.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0724 0400</institution-id><institution>Department of Pediatrics, Faculty of Medicine and Health Sciences, </institution><institution>Andrzej Frycz Modrzewski University, </institution></institution-wrap>Krakow, Poland </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>45</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496088</issue-id><elocation-id>212</elocation-id><history><date date-type="received"><day>19</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>9</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="296_2025_Article_5966.pdf"/><abstract id="Abs1"><p id="Par1">To estimate the actual incidence and prevalence of psoriatic arthritis (PsA) within a 9-year timeframe in Poland. Patients were defined as having PsA if they had at least two visits more than 90 days apart with ICD-10 codes M07.0, M07.1, M07.2, M07.3, or L40.5 and filled at least one reimbursed prescription for peripheral or axial PsA-specific treatments during this period (including methotrexate, sulfasalazine, ciclosporin, leflunomide, biologics, targeted synthetic drugs, or non-steroidal anti-inflammatory drugs). Data was obtained from the nationwide public payer database, considering gender, age, and region of residence. We observed an incidence rate of 1.1 per 100,000 inhabitants in 2021, compared to 13.2 in 2013. Regarding the age of the first diagnosis, the peak incidence rate decreased, with a more pronounced decline in men. The prevalence of PsA rose from 72.5 individuals per 100,000 in 2013 to 95.5 in 2021, representing approximately 0.1% of the total population in Poland, with a significant predominance of women among patients over 55 years of age. The decline in PsA incidence may be influenced by a strict case definition and improved access to treatment. Higher prevalence in older women suggests potential gender-related differences. The lower peak incidence and younger diagnosis age in men raise questions about whether lower PsA prevalence in older males is linked to higher mortality due to longer disease duration and comorbidities. Further research is needed to clarify these findings.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Psoriatic arthritis</kwd><kwd>Epidemiology</kwd><kwd>Incidence</kwd><kwd>Prevalence</kwd><kwd>Public health</kwd><kwd>Administrative data</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004895</institution-id><institution>European Social Fund</institution></institution-wrap></funding-source><award-id>POWR.05.02.00-00-0149/15</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100008530</institution-id><institution>European Regional Development Fund</institution></institution-wrap></funding-source><award-id>POPC.02.02.00-00-0015/18-00</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Psoriatic arthritis (PsA) is an inflammatory joint disease with a variable clinical presentation, most often, but not always, associated with the presence of skin or nail psoriasis. Due to the heterogeneous nature of symptoms, diagnosing PsA can be challenging, which may lead to under- or overestimation of incidence and prevalence data [<xref ref-type="bibr" rid="CR1">1</xref>]. The prevalence of PsA in published studies ranges from 0.05% [<xref ref-type="bibr" rid="CR2">2</xref>] to 0.25% [<xref ref-type="bibr" rid="CR3">3</xref>] in the general population, affecting between 6% and 41% of patients with psoriasis [<xref ref-type="bibr" rid="CR4">4</xref>]. The highest prevalence of PsA (0.26%) was reported in studies based on self-reports [<xref ref-type="bibr" rid="CR5">5</xref>]. The prevalence of PsA worldwide is estimated to be approximately 112/100,000 adults, although there is currently considerable variation due to the methodology of the studies conducted [<xref ref-type="bibr" rid="CR6">6</xref>] and geographical location [<xref ref-type="bibr" rid="CR5">5</xref>], and ranges in studies based solely on ICD-10 codes from 3.3/100,000 [<xref ref-type="bibr" rid="CR7">7</xref>] to 461.5/100,000 [<xref ref-type="bibr" rid="CR8">8</xref>]. In studies using administrative data, the prevalence of PsA averages 175/100,000 population in Europe and 147/100,000 population in North America, while even greater differences in PsA prevalence are seen in population-based studies (207/100,000 and 64/100,000 population in Europe and North America, respectively) [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par3">Planning strategies for the medical care of patients with PsA requires a comprehensive assessment of the severity of the problem. In practice, such an assessment is challenging due to the diversity of symptoms, the lack of diagnostic tests and the potential coexistence of other joint diseases in people with psoriasis. Well-designed population-based studies can provide data that are representative of the population as a whole, in addition to collecting information on demographics, lifestyle and environmental factors. Such studies can allow analysis of cause-and-effect relationships, but they can be time-consuming and costly, which may limit the recruitment of participants. Surveys based on administrative data, e.g. based on an ICD-10 code, may even cover the entire study population, which increases the statistical power of the results obtained and offers the possibility of assessing long-term trends, but it should be borne in mind that the quality of data obtained in this way may be heterogeneous and subject to error [<xref ref-type="bibr" rid="CR9">9</xref>]. The choice between population-based surveys and surveys based on administrative data depends on the objectives of the study and the specificity of the problem being analysed [<xref ref-type="bibr" rid="CR10">10</xref>]. Administrative health data, such as records of hospitalizations and prescription medications, are primarily generated for administrative purposes, such as billing and healthcare management, rather than being driven by predefined research objectives. Nevertheless, these datasets can be effectively repurposed to facilitate epidemiological studies [<xref ref-type="bibr" rid="CR11">11</xref>]. While there are relatively new studies based on single or complex administrative data on PsA epidemiology in some Western European countries [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>], comprehensive, nationwide studies based on complete case definitions are currently lacking. Previous estimates in Poland have been limited by reliance on single-source data [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par4">This study addresses this critical gap by providing a robust, nationwide analysis of PsA incidence and prevalence trends in Poland over a nine-year period (2013&#8211;2021). By utilizing comprehensive administrative data from the National Health Fund (NFH) and employing a strict case definition incorporating both diagnostic codes and treatment data, this study provides a more accurate and reliable assessment of current PsA epidemiology in Poland than previously available. The findings of this study may be of direct benefit to clinicians, providing a contemporary understanding of disease burden and trends, which can inform diagnostic and treatment decisions. Furthermore, health policy makers can leverage these results to optimize resource allocation and improve the quality of care for individuals with PsA in Poland. Specifically, the analysis of incidence trends, age of diagnosis, and gender disparities may inform public health initiatives aimed at early detection.</p></sec><sec id="Sec2"><title>Materials and methods</title><p id="Par5">We utilized electronic administrative health claims collected from 2009 to 2022 by the National Health Fund, a single public healthcare payer in Poland. The NHF database comprises individually reported data submitted to the payer by service providers, including detailed service descriptions and demographic variables that describe the patient. The data collected in databases are anonymous, but individual patients can be distinguished and matched by their IDs, which are pseudonymized national identification numbers.</p><sec id="Sec3"><title>Psoriatic arthritis definition</title><p id="Par6">Information on reported NHF health services and reimbursed prescriptions was used to define people with psoriatic arthritis.</p><p id="Par7">To exclude initial diagnoses reported as ICD-10 M07.0, M07.1, M07.2, M07.3 or L40.5 but not confirmed by further diagnosis, we developed a working definition of people with psoriatic arthritis. PsA patients were defined as persons who had at least two visits with ICD-10 codes M07.0, M07.1, M07.2, M07.3 or L40.5 in any type of service (outpatient or inpatient) more than 90 days apart and at the same time filled at least one reimbursable prescription for a drug whose active ingredient is methotrexate (ATC L01BA01, ATC L04AX03) or leflunomide (ATC L04AA13) or sulfasalazine (ATC A07EC01) or ciclosporin (ATC L04AD01, ATC S01XA18) or non-steroidal anti-inflammatory drugs (NSAIDs) including diclofenac (ATC M01AB05), piroxicam (ATC M01AC01), lornoxicam (ATC M01AC05), meloxicam (ATC M01AC06), ibuprofen (ATC M01AE01), naproxen (ATC M01AE02), ketoprofen (ATC M01AE03), tiaprofenic acid (ATC M01AE11), dexibuprofen (ATC M01AE14), dexketoprofen (ATC M01AE17), mefenamic acid (ATC M01AG01), celecoxib (ATC M01AH01), rofecoxib (ATC M01AH02), etoricoxib (ATC M01AH05) or biologics including etanercept (ATC L04AB01), infliximab (ATC L04AB02), adalimumab (ATC L04AB04), certolizumab pegol (ATC L04AB05), golimumab (ATC L04AB06), secukinumab (ATC L04AC10), ixekizumab (ATC L04AC13)) or targeted synthetic disease-modifying antirheumatic drug (tsDMRDs) tofacitinib (ATC L04AF01). Due to the lack of reimbursement in Poland in the studied period, the analysis did not include some biologics and tsDMRDs as guselkumab (ATC L04AC16), risankizumab (ATC L04AC18), bimekizumab (ATC L04AC21), ustekinumab (ATC L04AC05) and upadacitinib (ATC L04AF03).</p><p id="Par8">The date of diagnosis was considered the date of either the first treatment prescription or the first visit, whichever occurred earlier. The rationale for this approach is the possibility that a reimbursed prescription may have been issued during a private health care visit, as visits within the private health care system are not reported to the NHF, and completed reimbursed prescriptions, whether issued within the public or private health care system, are visible in the NHF databases. According to current standards for diagnosing PsA, the disease can be confirmed in individuals aged 16 years or older.</p></sec><sec id="Sec4"><title>Patients</title><p id="Par9">Databases from 2009 onwards were used to identify patients and determine their date of first diagnosis. However, due to access to reimbursed treatment data only since 2012, we assessed incidence from 2013 onwards to avoid the error of overestimating the incidence of PsA in 2012. Patients were classified as living in the urban or rural region based on the correct National Official Register of the Territorial Division of the Country (TERYT) code reported in the medical history of their first NHF-registered outpatient visit or hospitalization.</p></sec><sec id="Sec5"><title>Registered incidence and prevalence</title><p id="Par10">Registered incidence was defined as the number of new patients with a diagnosis of PsA reported through the publicly funded healthcare system in a calendar year. Registered prevalence in a given year was defined as the number of PsA patients alive on 31 December of that year in the NHF database. The Ministry of Digital Affairs&#8217; death register [<xref ref-type="bibr" rid="CR17">17</xref>] and information on the total population of Poland, provided by the Central Statistical Office [<xref ref-type="bibr" rid="CR18">18</xref>], were used to determine the prevalence.</p></sec><sec id="Sec6"><title>Statistics</title><p id="Par11">All database querying, data processing, computations, and visualisations were conducted using the GNU R programming language within the RStudio environment. Discrete variables were summarized with counts and proportions (N, %).</p><p id="Par12">The prevalence of PsA in Poland was calculated based on the presented NHF data and additional demographic data, including the number of Polish inhabitants, made available by the Central Statistical Office [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par13">To calculate standardised incidence and prevalence, we use data from the Central Statistical Office regarding the population size of a specific year. We employed standardised indicators for the entire Polish population to compare incidence and prevalence in Poland with those of other highly developed countries.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Incidence of PsA</title><p id="Par14">In 2021, 431 people were diagnosed with PsA in Poland, i.e. 1.1 per 100,000 people. In the period under analysis, the annual number of new diagnoses of PsA decreased. In 2013, the disease was diagnosed in 5098 people, which corresponds to 13.2 people per 100,000 population (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par15">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Registered incidence between 2013 and 2021 in the general population per 100,000 population</p></caption><graphic id="d33e412" position="float" orientation="portrait" xlink:href="296_2025_5966_Fig1_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec9"><title>Age at first diagnosis</title><p id="Par16">Between 2013 and 2021, the majority of new diagnoses of PsA were made in patients aged 35&#8211;55 years, regardless of gender. In 2021, the peak incidence of PsA occurred around the age of 45. (mean 44.8; median 45), earlier than in 2013. (mean 48.5; median 50). (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>).</p><p id="Par17">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Age distribution of the incidence of PsA in the Polish population in 2013 and 2021</p></caption><graphic id="d33e429" position="float" orientation="portrait" xlink:href="296_2025_5966_Fig2_HTML.jpg"/></fig>
</p><p id="Par18">We also observed a clear trend towards earlier incidence in men. In 2021, the peak incidence was 48 years for women and 39 years for men. (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). The median age of first diagnosis in 2021 was 47 years for women and 42 years for men.</p><p id="Par19">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Age distribution of incidence of PsA in 2021 by gender</p></caption><graphic id="d33e444" position="float" orientation="portrait" xlink:href="296_2025_5966_Fig3_HTML.jpg"/></fig>
</p><p id="Par20">Additionally, a slightly earlier age of onset of PsA was observed in rural areas. In 2021, the median age of diagnosis of PsA was 45 years in urban areas and 42 years in rural areas.</p></sec><sec id="Sec10"><title>The prevalence of PsA in Poland</title><p id="Par21">The prevalence of PsA in Poland was estimated at 0.098% in 2021, and the total number of living patients with PsA in Poland was 36,357 (31 December 2021), representing 95.5 per 100,000 population. A notable increase in prevalence was observed across the entire Polish population during the assessed period (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). The largest proportion of patients with PsA was observed among individuals aged 55&#8211;64 years (27% of all patients with PsA), while the smallest proportion was observed among patients younger than 18 years (0.2% of the total number of patients).</p><p id="Par22">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Registered morbidity from 2013 to 2021 in the general population per 100,000 population</p></caption><graphic id="d33e463" position="float" orientation="portrait" xlink:href="296_2025_5966_Fig4_HTML.jpg"/></fig>
</p><p id="Par23">Patients with PsA in Poland mainly live in urban areas &#8722;&#8201;69% of the total number of patients. This distribution is similar to that of the Polish population. The mean and median ages of patients living in urban areas (mean: 57.3 years, median: 60 years) are 3.5 and 5 years higher, respectively, than those living in rural areas. Half of all patients with PsA are urban dwellers aged 45&#8211;74 years (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). The differences in the age structure of patients with PsA living in urban and rural areas reflect differences in the age structure of the Polish population as a whole.</p><p id="Par24">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Number of all patients in Poland by age group and area of residence</p></caption><graphic id="d33e478" position="float" orientation="portrait" xlink:href="296_2025_5966_Fig5_HTML.jpg"/></fig>
</p><sec id="Sec11"><title>Prevalence by gender</title><p id="Par25">The highest prevalence in 2021, for both men and women, was in the sixth decade of life (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>). In 2021, about 61% of the total number of people diagnosed with PsA were women, with the percentage distribution changing with age. The number of female and male patients was relatively equal between 18 and 44 years of age, with a significant increase in female prevalence after 55 years of age &#8211; women accounted for 65% of patients in the 55&#8211;64 age group, 70% in the 65&#8211;74 age group and about 75% after 75 years of age.</p><p id="Par26">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Number of all patients with PsA in Poland in 2021 by age group and gender</p></caption><graphic id="d33e495" position="float" orientation="portrait" xlink:href="296_2025_5966_Fig6_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par27">The aim of our study was to assess the incidence and prevalence of PsA in Poland from 2013 to 2021 using administrative data from the National Health Fund in Poland. The study design aimed to exclude misdiagnosis as much as possible, so a strict patient definition was developed, taking into account simultaneously reported ICD-10 codes and PsA-dedicated treatment prescription fulfilment. We recognize that these exclusions could disproportionately affect certain subgroups of PsA patients and might introduce bias into our prevalence and incidence estimates. To mitigate this concern, we considered the balancing of specificity and sensitivity. The decision to use a stringent definition was a deliberate trade-off between specificity and sensitivity. We prioritized specificity to minimize the inclusion of false-positive cases, particularly given the reliance on administrative data and the potential for coding errors.</p><p id="Par28">We reported an incidence rate for PsA in 2021 of 1.1 per 100,000 inhabitants, which is more than ten times lower than in 2013. The most significant decline in newly diagnosed cases occurred between 2013 and 2017. Our analysis revealed gender differences in the age of first diagnosis throughout the study period, with peak incidence occurring nine years earlier for men. There were no significant differences in incidence between rural and urban areas. In contrast to incidence, there was a trend of increasing prevalence over the analysed period, most notably between 2013 and 2018, with numbers stabilizing in subsequent years. Data from the last analyzed year indicated that women make up the majority of the entire PsA patient population, clearly evident across all age groups starting from 55 years old.</p><p id="Par29">The marked decline in incidence is challenging to explain, but several potential factors should be considered. Firstly, it is possible that the higher incidence reported in 2013 reflects a primary overestimation due to the methodology of utilizing administrative data. At the beginning of the study period, the database might have included prevalent cases (patients already diagnosed before 2013) rather than solely representing new diagnoses within that year. The two-visit and one-prescription criteria, while aiming to ensure diagnostic accuracy, might not fully differentiate between new and existing cases at the beginning of the study period. We have attempted to mitigate this issue by including two visits with ICD-10 codes and filling at least one reimbursed prescription in the case definition. This was based on the assumption that patients with ongoing care are more likely to be properly diagnosed and identified in the database. However, we recognize that some individuals with pre-existing diagnoses may have met these criteria in 2013, contributing to an inflated initial incidence rate.</p><p id="Par30">However, we would like to highlight the significance of the relatively stable decrease in incidence rates observed in the later years of the study. After the initial sharp decline, the incidence appears to have stabilized at a trend, suggesting that the true new case incidence may be closer to the values observed in 2019&#8211;2021. It is also essential to emphasize that interpreting studies using administrative data necessitates careful consideration. While administrative databases provide valuable insights into population-level trends, they also present limitations related to coding accuracy, changes in diagnostic practices, and the inherent challenges of distinguishing between incident and prevalent cases, particularly at the beginning of the study period. Another possible explanation could be the previous overdiagnosis of psoriatic arthritis, possibly due to an earlier tendency to classify any arthritis or joint pain in patients with psoriasis as PsA. This may have been related to the slow introduction of the Classification of Arthritis in Psoriasis (CASPAR) criteria at that time [<xref ref-type="bibr" rid="CR19">19</xref>]. A noticeable lifestyle change is also observed, particularly among younger Poles, including a reduction in smoking and alcohol consumption - environmental factors that are often cited [<xref ref-type="bibr" rid="CR20">20</xref>]. Additionally, the lower prevalence of obesity in the general population among adult men and women in 2019 compared to 2013&#8211;2014 [<xref ref-type="bibr" rid="CR21">21</xref>], a recognized independent risk factor for PsA [<xref ref-type="bibr" rid="CR22">22</xref>], might also be of interest, although we have no data on whether this applies to a subpopulation with psoriasis. Another important aspect is the potential prevention of PsA development in patients with psoriasis resulting from the treatment used, including biologics [<xref ref-type="bibr" rid="CR23">23</xref>]. The increasing use of systemic treatment for severe psoriasis, including biological treatments, may also be significant in the Polish population since the number of psoriatic patients treated biologically increased from about 200 in 2013 to over 2000 in 2021 (based on unpublished NHF data). It can also not be ruled out that some patients with psoriasis treated biologically at dermatological centers meet the criteria for diagnosing PsA, but due to the effective treatment of skin and joint lesions under the care of a dermatologist, the diagnosis of PsA was not added. According to the NHF data, these patients are still categorized only as having psoriasis. While the significantly increased availability of biological treatments for psoriasis after 2019 may partially explain the latest incidence data, it does not account for the substantial decrease in the number of new patients between 2013 and 2017 by approximately 4000. Despite attempts to validate potential contributing factors through existing literature and data, the exact causes for the observed decline remain speculative.</p><p id="Par31">Worldwide data on the incidence of PsA in the general population are limited and largely outdated. Additionally, there are significant variations in published studies depending on the methodology and geographical location. In Europe, the highest incidence (41.3 per 100,000 population) was reported in Norway in 2015, based on a survey conducted between 2000 and 2008 [<xref ref-type="bibr" rid="CR24">24</xref>]. This contrasts sharply with the results of another Norwegian population-based survey conducted between 1978 and 1996, which reported 6.9 per 100,000 population [<xref ref-type="bibr" rid="CR25">25</xref>]. A high incidence (23 per 100,000 population) was also observed in Scandinavia in a Finnish survey conducted in 2000 [<xref ref-type="bibr" rid="CR26">26</xref>]. PsA was diagnosed much less frequently in Central and Southern Europe. In the population of two regions in the Czech Republic, a survey based on administrative data conducted in 2002&#8211;2003 reported 3.6 new cases per 100,000 inhabitants [<xref ref-type="bibr" rid="CR3">3</xref>]. A similar incidence was documented in a comparable study conducted in Greece between 1982 and 2001 (3.02 per 100,000 population) [<xref ref-type="bibr" rid="CR27">27</xref>] and in a Turkish retrospective study between 2003 and 2012 (2.8 per 100,000 population) [<xref ref-type="bibr" rid="CR28">28</xref>]. In a recent European study utilizing administrative data from the French National Health Insurance Database and the French National Hospital Discharge Database, the incidence, determined by disease code assigned in hospital or outpatient care (one hospital or outpatient visit was sufficient), was 8.4 per 100,000 population from 2015 to 2018 [<xref ref-type="bibr" rid="CR12">12</xref>]. In their study, Scott et al. qualified cases of patients with a single diagnosis code assigned by a primary care physician. The incidence in this study increased from 12.2 per 100,000 in 2012 to 17. 2 per 100,000 in 2019, before sharply falling to 5.6 per 100,000 in 2020 [<xref ref-type="bibr" rid="CR13">13</xref>]. Non-European reports on the magnitude of PsA incidence also vary. The lowest incidence was documented in a Japanese survey-based report (0.1 per 100,000) [<xref ref-type="bibr" rid="CR29">29</xref>]. A retrospective North American study based on data from 1970 to 1999 in Olmsted County, Minnesota, USA, estimated the incidence at 7.2 per 100,000 population [<xref ref-type="bibr" rid="CR30">30</xref>], as did a South American paper estimating the incidence of PsA from 2000 to 2005 at 8.3 per 100,000 [<xref ref-type="bibr" rid="CR31">31</xref>] and an Israeli study using data from the Clalit Health Services (CHS) database, where the incidence averaged 10. 9 per 100,000 from 2006 to 2015 [<xref ref-type="bibr" rid="CR32">32</xref>]. Direct comparisons of PsA incidence trends observed in our work and other studies [<xref ref-type="bibr" rid="CR13">13</xref>] are challenging due to significant methodological differences, including variations in case definitions and reporting methods. Unfortunately, there is a paucity of comparable, long-term data on PsA incidence across different countries. Many studies focus on prevalence rather than incidence. Further research is needed to establish whether declining PsA incidence trends have been observed elsewhere. The lack of standardized methodology makes it difficult to determine whether the sharp decline observed in Poland is truly unique or simply a reflection of these methodological differences.</p><p id="Par32">We observed the peak incidence of PsA in 2021 at 45 years of age, and most new diagnoses were made between 35 and 55 years of age, slightly earlier than in the studies by Alamanos et al. [<xref ref-type="bibr" rid="CR27">27</xref>] and Scott et al. [<xref ref-type="bibr" rid="CR13">13</xref>], where the peak incidence was between 45 and 64 years of age.</p><p id="Par33">More studies have been published on the prevalence of PsA. In our study, the prevalence has been increasing since 2013 and was 95.5 per 100,000 population in 2021, representing about 0.1% of the general population, of which more than 60% were women. The highest prevalence in 2021 was in women&#8217;s and men&#8217;s sixth decade of life. A previous study of the Polish population, using only ICD-10 codes without additional conditions, estimated a prevalence of 73.1 per 100,000 in 2018, representing 0.073% of the population [<xref ref-type="bibr" rid="CR16">16</xref>], which is consistent with our 2013 findings. In a recent meta-analysis using administrative data studies, the estimated mean prevalence of PsA worldwide was 109/100,000 [<xref ref-type="bibr" rid="CR6">6</xref>]. Similar to population-based studies, significant differences in prevalence are observed in studies based on administrative data. In population-based studies, prevalence ranges from 13/100,000 in Kuwait, in a study using questionnaires with subsequent physician confirmation [<xref ref-type="bibr" rid="CR33">33</xref>], to 580/100,000 in Spain, in a study using telephone interview data confirmed by discussion with a physician [<xref ref-type="bibr" rid="CR34">34</xref>]. Morbidity in European studies using administrative data ranged from 56.6/100,000 of the Greek population [<xref ref-type="bibr" rid="CR27">27</xref>] to 461.5/100,000 in a Norwegian study based on a patient definition requiring at least two visits with the corresponding ICD-10 code [<xref ref-type="bibr" rid="CR8">8</xref>]. In three other European studies using ICD-10 codes without an elaborate patient definition based on a single disease code reported to the database, the prevalence was 0.32% in the Danish population [<xref ref-type="bibr" rid="CR14">14</xref>], 0.3% in the German population [<xref ref-type="bibr" rid="CR15">15</xref>] and 0.28% in the United Kingdom [<xref ref-type="bibr" rid="CR13">13</xref>]. In our study, despite the decrease in incidence, we observed a significant 30% increase in prevalence from 72.5/100,000 in 2013 to 95.5/100,000 in 2021. One possible explanation is improving patient survival, which might be associated with better treatment of the underlying disease and comorbidities. Other studies have reported increasing trends, even a doubling of the number of patients over the observed periods [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. In our study, we observed the growing prevalence in the general population and the growing percentage of women with PsA in older age groups, which may indicate a better survival rate in women and a lower survival rate in men in the observed period. The younger age at diagnosis of PsA, and therefore longer disease duration in men may lead to a higher rate of comorbidities after age 55 [<xref ref-type="bibr" rid="CR35">35</xref>], which might impact survival, but this would require confirmation in further studies. Such relevant differences in prevalence do not occur in people under 55 years of age, and the absolute number of PsA men decreases after the age of 65, while the number of women is still stable.</p><p id="Par34">In our study, women were more frequently affected by PsA, accounting for 61% of all patients, which aligns with findings from European studies, including the population-based study by D&#246;nmez et al. [<xref ref-type="bibr" rid="CR28">28</xref>] and studies utilizing administrative data by Kerola et al. [<xref ref-type="bibr" rid="CR8">8</xref>], Tekin et al. [<xref ref-type="bibr" rid="CR14">14</xref>], and Grellmann et al. [<xref ref-type="bibr" rid="CR15">15</xref>]. A slight prevalence advantage for men over women has been noted in a retrospective study of the US population [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par35">The European and global data presented are extremely difficult to compare due to methodological differences. The Polish data on PsA incidence in 2013 are between those presented in the northern and southern European papers. Despite the low incidence of PsA in 2021 found in our study is difficult to explain, we cannot exclude similar changes in epidemiology in other populations using similar study methods. In addition to methodological differences, the observed differences in incidence and prevalence may be influenced by differences in the prevalence of psoriasis in different populations. Psoriasis occurs in 0.47% of the population in Poland [<xref ref-type="bibr" rid="CR16">16</xref>], much more frequently in Norway (3.8%&#8722;4.6%) [<xref ref-type="bibr" rid="CR36">36</xref>], Germany (1.90%&#8211;2.51%) [<xref ref-type="bibr" rid="CR37">37</xref>] and the USA (3%) [<xref ref-type="bibr" rid="CR38">38</xref>], and much less frequently in Japan (0.34%) [<xref ref-type="bibr" rid="CR39">39</xref>]. While our data do not directly assess treatment effectiveness or long-term outcomes, it is reasonable to speculate that improvements in PsA management may be contributing to the observed trends. Our data are also vital in terms of determining the level of access to innovative PsA treatment in Poland. In an earlier study, due to the lack of precise epidemiological data based on a constant number of PsA patients in the analysed timeframe, the estimated percentage of patients using biologic therapy/Janus kinase inhibitors in 2013, 2016, 2019 and 2022 was 1.4, 2.5, 4.5 and 8.7%, respectively [<xref ref-type="bibr" rid="CR40">40</xref>]. Taking into account current epidemiological data and the number of patients treated in particular years, the percentage of patients treated innovatively should be recalculated to 2.5, 3.6, 6.2% in 2013, 2016, 2019, respectively, and as 9.2&#8211;12.1% in 2021&#8211;2022, which means better availability in this group of patients than previously estimated. Better availability may result in better patient prognosis at the population level. The increasing prevalence of PsA despite declining incidence likely reflects a complex interplay of factors, including not only potential improvements in treatment but also changes in diagnostic practices, increased awareness of the disease, and aging of the population. It is possible that better treatment options are contributing to increased survival rates among individuals with PsA. However, further research is needed to confirm this hypothesis and to quantify the precise impact of treatment on long-term outcomes and prevalence trends.</p><p id="Par36">A strength of our analysis is that the results were compiled using data on all persons defined as PsA patients diagnosed and treated in the public health system in Poland between 2013 and 2021. In addition, a strict case definition, including two visits and prescription fulfilment, influenced the elimination of potentially unconfirmed diagnoses (treated by clinicians as suspected PsA but reported as PsA). To make the incidence study as robust as possible, we reviewed the incidence of specific ICD-10 codes three years before the analysis period and estimated the incidence in 2021 only after obtaining complete data for 2022. The importance of these results lies in the fact that, after excluding questionable cases and accounting for potential underestimation, we can confidently assert that the data presented are not overestimated.</p><p id="Par37">Our study has certain limitations. The limited timeframe of the presented analysis may affect the interpretation of the trend. This analysis only includes patients treated by public medical services. It is possible that some patients did not receive public specialist services between 2012 and 2021 but only private medical care, which prevented their administrative identification as PsA patients. Notably, the proportion of PsA patients in Poland treated exclusively in private healthcare seems to be negligible. In contrast to other studies using administrative data, to avoid overestimation of the problem being studied, we decided to include the need for a relevant prescription in the patient definition. This definition may lead to the exclusion from the study of genuine PsA cases in several scenarios: it might have excluded patients in long-term remission either spontaneously or through successful treatment, who might not require ongoing pharmacologic therapy at a specific time and therefore would not meet our prescription criterion, even if they still carry the diagnosis, patients who experienced diagnostic delays or gaps in care, leading to periods where they don&#8217;t have both the required diagnostic codes and a current prescription and patients with psoriasis who were treated with disease-modifying therapies (conventional and targeted) and achieved early suppression of joint symptoms, preventing a subsequent diagnosis of PsA. However, it also excluded patients with joint complaints other than PsA. Restrictions in access to health care system services during the COVID-19 pandemic in 2020&#8211;2021, which occurred predominantly in low and middle-income countries (LAMI) [<xref ref-type="bibr" rid="CR41">41</xref>], also to some extent in the rheumatology sector in Poland [<xref ref-type="bibr" rid="CR40">40</xref>] may have negatively influenced the number of new PsA cases registered according to our methodology. While diagnostic and reporting delays likely contributed to this decline, our data do not allow for a detailed statistical adjustment or focused analysis of this specific period. This is a limitation of our study, and further research is needed to quantify the precise impact of the pandemic on PsA epidemiology in Poland. On the other hand, the inclusion of NSAIDs in the analysis, the primary treatment option for axial disease, may have resulted in an overestimation of the values because we could have classified patients with psoriasis and arthralgia as PsA, which the physician incorrectly identified as suspected PsA, although this seems of little consequence. While we have discussed potential contributing factors, including improved diagnostic accuracy and earlier biologic therapies, it is possible that the higher incidence reported in 2013 reflects an overestimation due to our methodology. At the beginning of the study period, the administrative database might have included prevalent cases (patients already diagnosed before 2013) alongside new diagnoses, potentially inflating the initial incidence rate. The application of our case definition (two visits with ICD-10 codes and at least one reimbursed prescription) might not fully differentiate between new and existing cases at the study&#8217;s commencement. The relatively stable incidence rates observed in the later years of the study are encouraging but must be viewed within the context of the limitations of the data source. Finally, interpreting studies using administrative data requires careful consideration as they may present limitations related to coding accuracy, changes in diagnostic practices, and the inherent challenges of differentiating between incident and prevalent cases, particularly at the beginning of the study period.</p><p id="Par38">To our knowledge, the study presented is the first based on a very precise patient definition that includes separate visits and prescription fulfilment. Similar definitions have been used in recently published epidemiological studies on rheumatoid arthritis and juvenile idiopathic arthritis [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Many factors may influence the epidemiology of PsA; however, the described differences in incidence and prevalence are unlikely to be explained solely by geographical location, genetic predisposition, or access to healthcare. The epidemiology of PsA appears to be changing and requires up-to-date, large-scale studies in different populations, preferably using similar methodological assumptions.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors acknowledge that preliminary results from this study were presented at the Central European Congress of Rheumatology (CECR) 2024. The abstract was published in <italic toggle="yes">Rheumatology Forum</italic>, 2024, vol. 10, e-Suppl. A, 23&#8211;24 (Krajewska-W&#322;odarczyk M).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>M.K-W, B.B, M.S., B.K and Z.&#379;. conceptualised the study. M.K-W., M.Sz, Z.&#379;., M.O., K.P., J.S., M.&#346;., D.W., A.&#379;. M.S., M.B., A.&#346;, B.K and B.B. contributed to methodology. M.Sz., M.O., K.P., J.S., M.&#346;., D.W., and A.&#379; undertook data analysis. M.K-W., M.Sz. and M.S wrote the first draft of the manuscript. M.K-W, M.Sz., B.B, M.S., M.&#346;., B.K. and Z.&#379;. supervised the study. M.Sz., M.O., K.P., J.S., M.&#346;., D.W., and A.&#379;. were involved with funding acquisition. All authors contributed to a critical revision of the manuscript for important intellectual content. All authors agreed to the final version of the manuscript. All authors take full responsibility for the integrity and accuracy of all aspects of the work.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This paper was prepared as a part of the &#8220;Maps of Health Needs &#8211; Database of Systematic and Implementation Analysis&#8221; (grant number POWR.05.02.00-00-0149/15) and &#8216;Integrated Analytical Platform&#8217; projects (grant number POPC.02.02.00-00-0015/18&#8201;&#8722;&#8201;00), both co-financed by the European Union from the European Social Fund and European Regional Development Fund respectively. Open access funding provided by the University of Warmia and Mazury in Olsztyn.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data in this study were obtained with the permission of the Ministry of Health of the Republic of Poland from electronic databases of the National Health Fund (NFZ). Datasets are not publicly available because they contain sensitive data at an individual level. Aggregated data may be requested from the Department of Analyses and Strategies in the Ministry of Health in accordance with the provisions on access to public information (a justification for the public interest is required).</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par39">The authors declare that they have no conflicts of interest.</p></notes><notes id="FPar2"><title>Ethical approval</title><p id="Par40">This analysis relies solely on data obtained from the National Health Fund (NFZ) electronic databases. Obtaining institutional ethical approval was not required.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coates</surname><given-names>LC</given-names></name><name name-style="western"><surname>Helliwell</surname><given-names>PS</given-names></name></person-group><article-title>Psoriatic arthritis: state of the art review</article-title><source>Clin Med (Lond)</source><year>2017</year><volume>17</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.7861/clinmedicine.17-1-65</pub-id><pub-id pub-id-type="pmid">28148584</pub-id><pub-id pub-id-type="pmcid">PMC6297592</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Coates LC, Helliwell PS (2017) Psoriatic Arthritis: state of the Art review. Clin Med (Lond) 17:65&#8211;70. 10.7861/clinmedicine.17-1-65<pub-id pub-id-type="pmid">28148584</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7861/clinmedicine.17-1-65</pub-id><pub-id pub-id-type="pmcid">PMC6297592</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cak&#305;r</surname><given-names>N</given-names></name><name name-style="western"><surname>Pamuk</surname><given-names>&#214;N</given-names></name><name name-style="western"><surname>Dervi&#351;</surname><given-names>E</given-names></name><name name-style="western"><surname>Imery&#252;z</surname><given-names>N</given-names></name><name name-style="western"><surname>Uslu</surname><given-names>H</given-names></name><name name-style="western"><surname>Benian</surname><given-names>&#214;</given-names></name><name name-style="western"><surname>Elel&#231;i</surname><given-names>E</given-names></name><name name-style="western"><surname>Erdem</surname><given-names>G</given-names></name><name name-style="western"><surname>Sarvan</surname><given-names>FO</given-names></name><name name-style="western"><surname>Senocak</surname><given-names>M</given-names></name></person-group><article-title>The prevalences of some rheumatic diseases in Western Turkey: Havsa study</article-title><source>Rheumatol Int</source><year>2012</year><volume>32</volume><fpage>895</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1007/s00296-010-1699-4</pub-id><pub-id pub-id-type="pmid">21229358</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Cak&#305;r N, Pamuk &#214;N, Dervi&#351; E, Imery&#252;z N, Uslu H, Benian &#214;, Elel&#231;i E, Erdem G, Sarvan FO, Senocak M (2012) The prevalences of some rheumatic diseases in Western Turkey: Havsa study. Rheumatol Int 32:895&#8211;908. 10.1007/s00296-010-1699-4<pub-id pub-id-type="pmid">21229358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00296-010-1699-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanova</surname><given-names>P</given-names></name><name name-style="western"><surname>Pavelka</surname><given-names>K</given-names></name><name name-style="western"><surname>Holcatova</surname><given-names>I</given-names></name><name name-style="western"><surname>Pikhart</surname><given-names>H</given-names></name></person-group><article-title>Incidence and prevalence of psoriatic arthritis, ankylosing spondylitis, and reactive arthritis in the first descriptive population-based study in the Czech Republic</article-title><source>Scand J Rheumatol</source><year>2010</year><volume>39</volume><fpage>310</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.3109/03009740903544212</pub-id><pub-id pub-id-type="pmid">20476864</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Hanova P, Pavelka K, Holcatova I, Pikhart H (2010) Incidence and prevalence of psoriatic arthritis, ankylosing spondylitis, and reactive arthritis in the first descriptive population-based study in the Czech Republic. Scand J Rheumatol 39:310&#8211;317. 10.3109/03009740903544212<pub-id pub-id-type="pmid">20476864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/03009740903544212</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogdie</surname><given-names>A</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>P</given-names></name></person-group><article-title>The epidemiology of psoriatic arthritis</article-title><source>Rheum Dis Clin North Am</source><year>2015</year><volume>4</volume><fpage>545</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.rdc.2015.07.001</pub-id><pub-id pub-id-type="pmcid">PMC4610151</pub-id><pub-id pub-id-type="pmid">26476218</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Ogdie A, Weiss P (2015) The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 4:545&#8211;568. 10.1016/j.rdc.2015.07.001<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.rdc.2015.07.001</pub-id><pub-id pub-id-type="pmcid">PMC4610151</pub-id><pub-id pub-id-type="pmid">26476218</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stolwijk</surname><given-names>C</given-names></name><name name-style="western"><surname>van Onna</surname><given-names>M</given-names></name><name name-style="western"><surname>Boonen</surname><given-names>A</given-names></name><name name-style="western"><surname>van Tubergen</surname><given-names>A</given-names></name></person-group><article-title>Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis</article-title><source>Arthritis Care Res (Hoboken)</source><year>2016</year><volume>68</volume><fpage>1320</fpage><lpage>1331</lpage><pub-id pub-id-type="doi">10.1002/acr.22831</pub-id><pub-id pub-id-type="pmid">26713432</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Stolwijk C, van Onna M, Boonen A, van Tubergen A (2016) Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. Arthritis Care Res (Hoboken) 68:1320&#8211;1331. 10.1002/acr.22831<pub-id pub-id-type="pmid">26713432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acr.22831</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lembke</surname><given-names>S</given-names></name><name name-style="western"><surname>Macfarlane</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Jones</surname><given-names>GT</given-names></name></person-group><article-title>The worldwide prevalence of psoriatic arthritis-a systematic review and meta-analysis</article-title><source>Rheumatology (Oxford)</source><year>2024</year><volume>63</volume><fpage>3211</fpage><lpage>3220</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/keae198</pub-id><pub-id pub-id-type="pmid">38530786</pub-id><pub-id pub-id-type="pmcid">PMC11637478</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Lembke S, Macfarlane GJ, Jones GT (2024) The worldwide prevalence of psoriatic arthritis-a systematic review and meta-analysis. Rheumatology (Oxford) 63:3211&#8211;3220. 10.1093/rheumatology/keae198<pub-id pub-id-type="pmid">38530786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/keae198</pub-id><pub-id pub-id-type="pmcid">PMC11637478</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>J&#250;nior</surname><given-names>DST</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>CM</given-names></name><name name-style="western"><surname>de Assis</surname><given-names>EM</given-names></name></person-group><article-title>Population-based study of 24 autoimmune diseases carried out in a Brazilian microregion</article-title><source>J Epidemiol Glob Health</source><year>2019</year><volume>9</volume><fpage>243</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.2991/jegh.k.190920.001</pub-id><pub-id pub-id-type="pmid">31854165</pub-id><pub-id pub-id-type="pmcid">PMC7310795</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">J&#250;nior DST, de Oliveira CM, de Assis EM (2019) Population-based study of 24 autoimmune diseases carried out in a Brazilian microregion. J Epidemiol Glob Health 9:243&#8211;251. 10.2991/jegh.k.190920.001<pub-id pub-id-type="pmid">31854165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2991/jegh.k.190920.001</pub-id><pub-id pub-id-type="pmcid">PMC7310795</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerola</surname><given-names>AM</given-names></name><name name-style="western"><surname>Rollefstad</surname><given-names>S</given-names></name><name name-style="western"><surname>Kazemi</surname><given-names>A</given-names></name><name name-style="western"><surname>Wibetoe</surname><given-names>G</given-names></name><name name-style="western"><surname>Sexton</surname><given-names>J</given-names></name><name name-style="western"><surname>Mars</surname><given-names>N</given-names></name><name name-style="western"><surname>Kauppi</surname><given-names>M</given-names></name><name name-style="western"><surname>Kvien</surname><given-names>TK</given-names></name><name name-style="western"><surname>Haavardsholm</surname><given-names>EA</given-names></name><name name-style="western"><surname>Semb</surname><given-names>AG</given-names></name></person-group><article-title>Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents</article-title><source>Scand J Rheumatol</source><year>2023</year><volume>52</volume><fpage>42</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1080/03009742.2021.1997436</pub-id><pub-id pub-id-type="pmid">35014920</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Kerola AM, Rollefstad S, Kazemi A, Wibetoe G, Sexton J, Mars N, Kauppi M, Kvien TK, Haavardsholm EA, Semb AG (2023) Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents. Scand J Rheumatol 52:42&#8211;50. 10.1080/03009742.2021.1997436<pub-id pub-id-type="pmid">35014920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/03009742.2021.1997436</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emerson</surname><given-names>SD</given-names></name><name name-style="western"><surname>McLinden</surname><given-names>T</given-names></name><name name-style="western"><surname>Sereda</surname><given-names>P</given-names></name><name name-style="western"><surname>Yonkman</surname><given-names>AM</given-names></name><name name-style="western"><surname>Trigg</surname><given-names>J</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>S</given-names></name><name name-style="western"><surname>Hogg</surname><given-names>RS</given-names></name><name name-style="western"><surname>Salters</surname><given-names>KA</given-names></name><name name-style="western"><surname>Lima</surname><given-names>VD</given-names></name><name name-style="western"><surname>Barrios</surname><given-names>R</given-names></name></person-group><article-title>Secondary use of routinely collected administrative health data for epidemiologic research: answering research questions using data collected for a different purpose</article-title><source>Int J Popul Data Sci</source><year>2024</year><volume>9</volume><issue>1</issue><fpage>2407</fpage><pub-id pub-id-type="doi">10.23889/ijpds.v9i1.2407</pub-id><pub-id pub-id-type="pmid">39620116</pub-id><pub-id pub-id-type="pmcid">PMC11606632</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Emerson SD, McLinden T, Sereda P, Yonkman AM, Trigg J, Peterson S, Hogg RS, Salters KA, Lima VD, Barrios R (2024) Secondary use of routinely collected administrative health data for epidemiologic research: answering research questions using data collected for a different purpose. Int J Popul Data Sci 9(1):2407. 10.23889/ijpds.v9i1.2407<pub-id pub-id-type="pmid">39620116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23889/ijpds.v9i1.2407</pub-id><pub-id pub-id-type="pmcid">PMC11606632</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Connelly</surname><given-names>R</given-names></name><name name-style="western"><surname>Playford</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Gayle</surname><given-names>V</given-names></name><name name-style="western"><surname>Dibben</surname><given-names>C</given-names></name></person-group><article-title>The role of administrative data in the big data revolution in social science research</article-title><source>Soc Sci Res</source><year>2016</year><volume>59</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.ssresearch.2016.04.015</pub-id><pub-id pub-id-type="pmid">27480367</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Connelly R, Playford CJ, Gayle V, Dibben C (2016) The role of administrative data in the big data revolution in social science research. Soc Sci Res 59:1&#8211;12. 10.1016/j.ssresearch.2016.04.015<pub-id pub-id-type="pmid">27480367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ssresearch.2016.04.015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGrail</surname><given-names>K</given-names></name><name name-style="western"><surname>Jones</surname><given-names>K</given-names></name></person-group><article-title>Population data science: the science of data about people</article-title><source>Int J Popul Data Sci</source><year>2018</year><pub-id pub-id-type="doi">10.23889/ijpds.v3i4.918</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">McGrail K, Jones K (2018) Population Data Science: The science of data about people. Int J Popul Data Sci 3(4). 10.23889/ijpds.v3i4.918.<pub-id pub-id-type="pmid">34095517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23889/ijpds.v3i1.415</pub-id><pub-id pub-id-type="pmcid">PMC8142960</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pina Vegas</surname><given-names>L</given-names></name><name name-style="western"><surname>Sbidian</surname><given-names>E</given-names></name><name name-style="western"><surname>Penso</surname><given-names>L</given-names></name><name name-style="western"><surname>Claudepierre</surname><given-names>P</given-names></name></person-group><article-title>Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database</article-title><source>Rheumatology (Oxford)</source><year>2021</year><volume>60</volume><fpage>1243</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/keaa448</pub-id><pub-id pub-id-type="pmid">32911531</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Pina Vegas L, Sbidian E, Penso L, Claudepierre P (2021) Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database. Rheumatology (Oxford) 60:1243&#8211;1251. 10.1093/rheumatology/keaa448<pub-id pub-id-type="pmid">32911531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/keaa448</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>IC</given-names></name><name name-style="western"><surname>Whittle</surname><given-names>R</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>J</given-names></name><name name-style="western"><surname>Twohig</surname><given-names>H</given-names></name><name name-style="western"><surname>Hider</surname><given-names>SL</given-names></name><name name-style="western"><surname>Mallen</surname><given-names>CD</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>KP</given-names></name></person-group><article-title>Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: an observational study using primary care electronic health record data</article-title><source>Lancet Reg Health</source><year>2022</year><volume>23</volume><fpage>100519</fpage><pub-id pub-id-type="doi">10.1016/j.lanepe.2022.100519</pub-id><pub-id pub-id-type="pmcid">PMC9557034</pub-id><pub-id pub-id-type="pmid">36246147</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Scott IC, Whittle R, Bailey J, Twohig H, Hider SL, Mallen CD, Muller S, Jordan KP (2022) Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: an observational study using primary care electronic health record data. Lancet Reg Health 23:100519. 10.1016/j.lanepe.2022.100519<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lanepe.2022.100519</pub-id><pub-id pub-id-type="pmcid">PMC9557034</pub-id><pub-id pub-id-type="pmid">36246147</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tekin</surname><given-names>HG</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Burge</surname><given-names>R</given-names></name><name name-style="western"><surname>Birt</surname><given-names>J</given-names></name><name name-style="western"><surname>Egeberg</surname><given-names>A</given-names></name></person-group><article-title>Burden and disease characteristics of patients with psoriatic arthritis: a population-based cross-sectional study</article-title><source>J Rheumatol</source><year>2019</year><volume>46</volume><fpage>716</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.3899/jrheum.180670</pub-id><pub-id pub-id-type="pmid">30824662</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Tekin HG, Wu JJ, Burge R, Birt J, Egeberg A (2019) Burden and disease characteristics of patients with psoriatic arthritis: A Population-based Cross-sectional study. J Rheumatol 46:716&#8211;720. 10.3899/jrheum.180670<pub-id pub-id-type="pmid">30824662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3899/jrheum.180670</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grellmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Dombrowsky</surname><given-names>W</given-names></name><name name-style="western"><surname>Fabricius</surname><given-names>V</given-names></name><name name-style="western"><surname>Suruki</surname><given-names>R</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>A</given-names></name><name name-style="western"><surname>Joeres</surname><given-names>L</given-names></name></person-group><article-title>Epidemiology and treatment of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis in Germany: a real-world evidence study</article-title><source>Adv Ther</source><year>2021</year><volume>38</volume><fpage>366</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1007/s12325-020-01522-8</pub-id><pub-id pub-id-type="pmid">33128201</pub-id><pub-id pub-id-type="pmcid">PMC7854418</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Grellmann C, Dombrowsky W, Fabricius V, Suruki R, Sheahan A, Joeres L (2021) Epidemiology and treatment of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis in Germany: a real-world evidence study. Adv Ther 38:366&#8211;385. 10.1007/s12325-020-01522-8<pub-id pub-id-type="pmid">33128201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12325-020-01522-8</pub-id><pub-id pub-id-type="pmcid">PMC7854418</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>T&#322;ustochowicz</surname><given-names>M</given-names></name><name name-style="western"><surname>Wierzba</surname><given-names>W</given-names></name><name name-style="western"><surname>Marczak</surname><given-names>M</given-names></name><name name-style="western"><surname>T&#322;ustochowicz</surname><given-names>W</given-names></name><name name-style="western"><surname>&#346;liwczy&#324;ski</surname><given-names>A</given-names></name><name name-style="western"><surname>Raciborski</surname><given-names>F</given-names></name><name name-style="western"><surname>Kwiatkowska</surname><given-names>B</given-names></name><name name-style="western"><surname>Brzozowska</surname><given-names>M</given-names></name><name name-style="western"><surname>Jacyna</surname><given-names>A</given-names></name><name name-style="western"><surname>Kisiel</surname><given-names>B</given-names></name></person-group><article-title>Trends in psoriatic arthritis epidemiology in Poland</article-title><source>Rheumatol Int</source><year>2021</year><volume>41</volume><fpage>139</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1007/s00296-020-04734-x</pub-id><pub-id pub-id-type="pmid">33113001</pub-id><pub-id pub-id-type="pmcid">PMC7806568</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">T&#322;ustochowicz M, Wierzba W, Marczak M, T&#322;ustochowicz W, &#346;liwczy&#324;ski A, Raciborski F, Kwiatkowska B, Brzozowska M, Jacyna A, Kisiel B (2021) Trends in psoriatic arthritis epidemiology in Poland. Rheumatol Int 41:139&#8211;145. 10.1007/s00296-020-04734-x<pub-id pub-id-type="pmid">33113001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00296-020-04734-x</pub-id><pub-id pub-id-type="pmcid">PMC7806568</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Polish Ministry of Digital Affairs register. <ext-link ext-link-type="uri" xlink:href="https://www.gov.pl/web/cyfryzacja/rejestr-stanu-cywilnego">https://www.gov.pl/web/cyfryzacja/rejestr-stanu-cywilnego</ext-link>. Accessed 20 Nov 2024</mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Polish Central Statistical Office registe. <ext-link ext-link-type="uri" xlink:href="https://stat.gov.pl/obszary-tematyczne/ludnosc/ludnosc">https://stat.gov.pl/obszary-tematyczne/ludnosc/ludnosc</ext-link>. Accessed 20 Nov 2024</mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>FitzGerald</surname><given-names>O</given-names></name><name name-style="western"><surname>Ogdie</surname><given-names>A</given-names></name><name name-style="western"><surname>Chandran</surname><given-names>V</given-names></name><name name-style="western"><surname>Coates</surname><given-names>LC</given-names></name><name name-style="western"><surname>Kavanaugh</surname><given-names>A</given-names></name><name name-style="western"><surname>Tillett</surname><given-names>W</given-names></name><name name-style="western"><surname>Leung</surname><given-names>YY</given-names></name><name name-style="western"><surname>deWit</surname><given-names>M</given-names></name><name name-style="western"><surname>Scher</surname><given-names>JU</given-names></name><name name-style="western"><surname>Mease</surname><given-names>PJ</given-names></name></person-group><article-title>Psoriatic arthritis</article-title><source>Nat Rev Dis Primers</source><year>2021</year><volume>7</volume><fpage>59</fpage><pub-id pub-id-type="doi">10.1038/s41572-021-00293-y</pub-id><pub-id pub-id-type="pmid">34385474</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">FitzGerald O, Ogdie A, Chandran V, Coates LC, Kavanaugh A, Tillett W, Leung YY, deWit M, Scher JU, Mease PJ (2021) Psoriatic arthritis. Nat Rev Dis Primers 7:59. 10.1038/s41572-021-00293-y<pub-id pub-id-type="pmid">34385474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-021-00293-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owczarczyk-Saczonek</surname><given-names>A</given-names></name><name name-style="western"><surname>Kasprowicz-Furma&#324;czyk</surname><given-names>M</given-names></name><name name-style="western"><surname>Krajewska-W&#322;odarczyk</surname><given-names>M</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>C</given-names></name></person-group><article-title>Does the lifestyle of patients with psoriasis affect their illness?</article-title><source>Advances in hygiene and experimental medicine.</source><year>2021</year><volume>75</volume><fpage>643</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.2478/ahem-2021-0033</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Owczarczyk-Saczonek A, Kasprowicz-Furma&#324;czyk M, Krajewska-W&#322;odarczyk M, Griffiths C (2021) Does the lifestyle of patients with psoriasis affect their illness? Advances in hygiene and experimental medicine. 75:643&#8211;654. 10.2478/ahem-2021-0033</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">World obesity prevalence data &#8211; Poland. <ext-link ext-link-type="uri" xlink:href="https://data.worldobesity.org/country/poland-173/#data_prevalence">https://data.worldobesity.org/country/poland-173/#data_prevalence</ext-link>. Accessed 20 Nov 2024</mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#243;pez-Medina</surname><given-names>C</given-names></name><name name-style="western"><surname>McGonagle</surname><given-names>D</given-names></name><name name-style="western"><surname>Gossec</surname><given-names>L</given-names></name></person-group><article-title>Subclinical psoriatic arthritis and disease interception-where are we in 2024?</article-title><source>Rheumatology (Oxford).</source><year>2025</year><volume>64</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/keae399</pub-id><pub-id pub-id-type="pmid">39150442</pub-id><pub-id pub-id-type="pmcid">PMC11701312</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">L&#243;pez-Medina C, McGonagle D, Gossec L (2025) Subclinical psoriatic arthritis and disease interception-where are we in 2024? Rheumatology (Oxford). 64:56&#8211;64. 10.1093/rheumatology/keae399<pub-id pub-id-type="pmid">39150442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/keae399</pub-id><pub-id pub-id-type="pmcid">PMC11701312</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aronovich</surname><given-names>A</given-names></name><name name-style="western"><surname>Novikov</surname><given-names>I</given-names></name><name name-style="western"><surname>Pavlovsky</surname><given-names>L</given-names></name></person-group><article-title>Do biologic treatments for psoriasis lower the risk of psoriatic arthritis? A systematic review</article-title><source>Am J Clin Dermatol</source><year>2023</year><volume>24</volume><fpage>865</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1007/s40257-023-00801-8</pub-id><pub-id pub-id-type="pmid">37341960</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Aronovich A, Novikov I, Pavlovsky L (2023) Do biologic treatments for psoriasis lower the risk of psoriatic arthritis? A systematic review. Am J Clin Dermatol 24:865&#8211;873. 10.1007/s40257-023-00801-8<pub-id pub-id-type="pmid">37341960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40257-023-00801-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoff</surname><given-names>M</given-names></name><name name-style="western"><surname>Gulati</surname><given-names>AM</given-names></name><name name-style="western"><surname>Romundstad</surname><given-names>PR</given-names></name><name name-style="western"><surname>Kavanaugh</surname><given-names>A</given-names></name><name name-style="western"><surname>Haugeberg</surname><given-names>G</given-names></name></person-group><article-title>Prevalence and incidence rates of psoriatic arthritis in central Norway: data from the Nord-Tr&#248;ndelag health study (HUNT)</article-title><source>Ann Rheum Dis</source><year>2015</year><volume>74</volume><fpage>60</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2013-203862</pub-id><pub-id pub-id-type="pmid">23962458</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Hoff M, Gulati AM, Romundstad PR, Kavanaugh A, Haugeberg G (2015) Prevalence and incidence rates of psoriatic arthritis in central Norway: data from the Nord-Tr&#248;ndelag health study (HUNT). Ann Rheum Dis 74:60&#8211;64. 10.1136/annrheumdis-2013-203862<pub-id pub-id-type="pmid">23962458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2013-203862</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nossent</surname><given-names>JC</given-names></name><name name-style="western"><surname>Gran</surname><given-names>JT</given-names></name></person-group><article-title>Epidemiological and clinical characteristics of psoriatic arthritis in Northern Norway</article-title><source>Scand J Rheumatol</source><year>2009</year><volume>38</volume><fpage>251</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1080/03009740802609558</pub-id><pub-id pub-id-type="pmid">19247847</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Nossent JC, Gran JT (2009) Epidemiological and clinical characteristics of psoriatic arthritis in Northern Norway. Scand J Rheumatol 38:251&#8211;255. 10.1080/03009740802609558<pub-id pub-id-type="pmid">19247847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/03009740802609558</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savolainen</surname><given-names>E</given-names></name><name name-style="western"><surname>Kaipiainen-Sepp&#228;nen</surname><given-names>O</given-names></name><name name-style="western"><surname>Kr&#246;ger</surname><given-names>L</given-names></name><name name-style="western"><surname>Luosuj&#228;rvi</surname><given-names>R</given-names></name></person-group><article-title>Total incidence and distribution of inflammatory joint diseases in a defined population: results from the Kuopio 2000 arthritis survey</article-title><source>J Rheumatol</source><year>2003</year><volume>30</volume><fpage>2460</fpage><lpage>2468</lpage><pub-id pub-id-type="pmid">14677193</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Savolainen E, Kaipiainen-Sepp&#228;nen O, Kr&#246;ger L, Luosuj&#228;rvi R (2003) Total incidence and distribution of inflammatory joint diseases in a defined population: results from the Kuopio 2000 arthritis survey. J Rheumatol 30:2460&#8211;2468 PMID: 14677193<pub-id pub-id-type="pmid">14677193</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alamanos</surname><given-names>Y</given-names></name><name name-style="western"><surname>Papadopoulos</surname><given-names>NG</given-names></name><name name-style="western"><surname>Voulgari</surname><given-names>PV</given-names></name><name name-style="western"><surname>Siozos</surname><given-names>C</given-names></name><name name-style="western"><surname>Psychos</surname><given-names>DN</given-names></name><name name-style="western"><surname>Tympanidou</surname><given-names>M</given-names></name><name name-style="western"><surname>Drosos</surname><given-names>AA</given-names></name></person-group><article-title>Epidemiology of psoriatic arthritis in Northwest Greece, 1982&#8211;2001</article-title><source>J Rheumatol</source><year>2003</year><volume>30</volume><fpage>2641</fpage><lpage>2644</lpage><pub-id pub-id-type="pmid">14719208</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Alamanos Y, Papadopoulos NG, Voulgari PV, Siozos C, Psychos DN, Tympanidou M, Drosos AA (2003) Epidemiology of psoriatic arthritis in Northwest Greece, 1982&#8211;2001. J Rheumatol 30:2641&#8211;2644<pub-id pub-id-type="pmid">14719208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#246;nmez</surname><given-names>S</given-names></name><name name-style="western"><surname>Pamuk</surname><given-names>&#214;N</given-names></name><name name-style="western"><surname>Akker</surname><given-names>M</given-names></name><name name-style="western"><surname>Ak</surname><given-names>R</given-names></name></person-group><article-title>Clinical features and types of articular involvement in patients with psoriatic arthritis</article-title><source>Clin Rheumatol</source><year>2015</year><volume>34</volume><fpage>1091</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1007/s10067-014-2746-4</pub-id><pub-id pub-id-type="pmid">25066919</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">D&#246;nmez S, Pamuk &#214;N, Akker M, Ak R (2015) Clinical features and types of articular involvement in patients with psoriatic arthritis. Clin Rheumatol 34:1091&#8211;1096. 10.1007/s10067-014-2746-4<pub-id pub-id-type="pmid">25066919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10067-014-2746-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hukuda</surname><given-names>S</given-names></name><name name-style="western"><surname>Minami</surname><given-names>M</given-names></name><name name-style="western"><surname>Saito</surname><given-names>T</given-names></name><name name-style="western"><surname>Mitsui</surname><given-names>H</given-names></name><name name-style="western"><surname>Matsui</surname><given-names>N</given-names></name><name name-style="western"><surname>Komatsubara</surname><given-names>Y</given-names></name><name name-style="western"><surname>Makino</surname><given-names>H</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>T</given-names></name><name name-style="western"><surname>Shingu</surname><given-names>M</given-names></name><name name-style="western"><surname>Sakou</surname><given-names>T</given-names></name><name name-style="western"><surname>Shichikawa</surname><given-names>K</given-names></name></person-group><article-title>Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan ankylosing spondylitis society</article-title><source>J Rheumatol</source><year>2001</year><volume>28</volume><fpage>554</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">11296958</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Hukuda S, Minami M, Saito T, Mitsui H, Matsui N, Komatsubara Y, Makino H, Shibata T, Shingu M, Sakou T, Shichikawa K (2001) Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan ankylosing spondylitis society. J Rheumatol 28:554&#8211;549 PMID: 11296958<pub-id pub-id-type="pmid">11296958</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>FC</given-names></name><name name-style="western"><surname>Icen</surname><given-names>M</given-names></name><name name-style="western"><surname>Crowson</surname><given-names>CS</given-names></name><name name-style="western"><surname>McEvoy</surname><given-names>MT</given-names></name><name name-style="western"><surname>Gabriel</surname><given-names>SE</given-names></name><name name-style="western"><surname>Kremers</surname><given-names>HM</given-names></name></person-group><article-title>Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study</article-title><source>J Rheumatol</source><year>2009</year><volume>36</volume><fpage>361</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.3899/jrheum.080691</pub-id><pub-id pub-id-type="pmid">19208565</pub-id><pub-id pub-id-type="pmcid">PMC2717703</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM (2009) Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol 36:361&#8211;367. 10.3899/jrheum.080691<pub-id pub-id-type="pmid">19208565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3899/jrheum.080691</pub-id><pub-id pub-id-type="pmcid">PMC2717703</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soriano</surname><given-names>ER</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>J</given-names></name><name name-style="western"><surname>Velozo</surname><given-names>E</given-names></name><name name-style="western"><surname>Schpilberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Imamura</surname><given-names>PM</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>J</given-names></name><name name-style="western"><surname>Catoggio</surname><given-names>LJ</given-names></name></person-group><article-title>Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organisation-based study</article-title><source>Rheumatology (Oxford)</source><year>2011</year><volume>50</volume><fpage>729</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/keq369</pub-id><pub-id pub-id-type="pmid">21134962</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Soriano ER, Rosa J, Velozo E, Schpilberg M, Imamura PM, Diaz J, Catoggio LJ (2011) Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organisation-based study. Rheumatology (Oxford) 50:729&#8211;734. 10.1093/rheumatology/keq369<pub-id pub-id-type="pmid">21134962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/keq369</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eder</surname><given-names>L</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>AD</given-names></name><name name-style="western"><surname>Feldhamer</surname><given-names>I</given-names></name><name name-style="western"><surname>Greenberg-Dotan</surname><given-names>S</given-names></name><name name-style="western"><surname>Batat</surname><given-names>E</given-names></name><name name-style="western"><surname>Zisman</surname><given-names>D</given-names></name></person-group><article-title>The epidemiology of psoriatic arthritis in Israel&#8212;a population-based study</article-title><source>Arthritis Res Ther</source><year>2018</year><volume>20</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/s13075-017-1497-4</pub-id><pub-id pub-id-type="pmid">29329596</pub-id><pub-id pub-id-type="pmcid">PMC5795280</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Eder L, Cohen AD, Feldhamer I, Greenberg-Dotan S, Batat E, Zisman D (2018) The epidemiology of psoriatic arthritis in Israel - a population-based study. Arthritis Res Ther 20:3. 10.1186/s13075-017-1497-4<pub-id pub-id-type="pmid">29329596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13075-017-1497-4</pub-id><pub-id pub-id-type="pmcid">PMC5795280</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Awadhi</surname><given-names>AM</given-names></name><name name-style="western"><surname>Olusi</surname><given-names>SO</given-names></name><name name-style="western"><surname>Al-Saeid</surname><given-names>K</given-names></name><name name-style="western"><surname>Moussa</surname><given-names>M</given-names></name><name name-style="western"><surname>Shehab</surname><given-names>D</given-names></name><name name-style="western"><surname>Al-Zaid</surname><given-names>N</given-names></name><name name-style="western"><surname>Al-Herz</surname><given-names>A</given-names></name><name name-style="western"><surname>Al-Jarallah</surname><given-names>K</given-names></name></person-group><article-title>Musculoskeletal pain, disability and health-seeking behavior in adult Kuwaitis using a validated Arabic version of the WHO-ILAR COPCORD core questionnaire</article-title><source>Clin Exp Rheumatol</source><year>2004</year><volume>22</volume><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">15083885</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Al-Awadhi AM, Olusi SO, Al-Saeid K, Moussa M, Shehab D, Al-Zaid N, Al-Herz A, Al-Jarallah K (2004) Musculoskeletal pain, disability and health-seeking behavior in adult Kuwaitis using a validated Arabic version of the WHO-ILAR COPCORD core questionnaire. Clin Exp Rheumatol 22:177&#8211;183 PMID: 15083885<pub-id pub-id-type="pmid">15083885</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romero P&#233;rez</surname><given-names>A</given-names></name><name name-style="western"><surname>Queiro</surname><given-names>R</given-names></name><name name-style="western"><surname>Seoane-Mato</surname><given-names>D</given-names></name><name name-style="western"><surname>Graell</surname><given-names>E</given-names></name><name name-style="western"><surname>Chamizo</surname><given-names>E</given-names></name><name name-style="western"><surname>Chaves Chaparro</surname><given-names>L</given-names></name><name name-style="western"><surname>Rojas Herrera</surname><given-names>S</given-names></name><name name-style="western"><surname>Pons Dolset</surname><given-names>J</given-names></name><name name-style="western"><surname>Polo Ost&#225;riz</surname><given-names>MA</given-names></name><name name-style="western"><surname>Ruiz-Alejos Garrido</surname><given-names>S</given-names></name><name name-style="western"><surname>Mac&#237;a-Villa</surname><given-names>C</given-names></name><name name-style="western"><surname>Cruz-Valenciano</surname><given-names>A</given-names></name><name name-style="western"><surname>Gonz&#225;lez G&#243;mez</surname><given-names>ML</given-names></name><name name-style="western"><surname>S&#225;nchez-Piedra</surname><given-names>C</given-names></name><name name-style="western"><surname>D&#237;az-Gonz&#225;lez</surname><given-names>F</given-names></name><name name-style="western"><surname>Bustabad-Reyes</surname><given-names>S</given-names></name><collab>Proyecto EPISER2016 WorkingGroup</collab></person-group><article-title>Higher prevalence of psoriatic arthritis in the adult population in Spain? A population-based cross-sectional study</article-title><source>PLoS One</source><year>2020</year><volume>15</volume><fpage>e0234556</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0234556</pub-id><pub-id pub-id-type="pmid">32555622</pub-id><pub-id pub-id-type="pmcid">PMC7299392</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Romero P&#233;rez A, Queiro R, Seoane-Mato D, Graell E, Chamizo E, Chaves Chaparro L, Rojas Herrera S, Pons Dolset J, Polo Ost&#225;riz MA, Ruiz-Alejos Garrido S, Mac&#237;a-Villa C, Cruz-Valenciano A, Gonz&#225;lez G&#243;mez ML, S&#225;nchez-Piedra C, D&#237;az-Gonz&#225;lez F, Bustabad-Reyes S, Proyecto EPISER2016 WorkingGroup (2020) Higher prevalence of psoriatic arthritis in the adult population in Spain? A population-based cross-sectional study. PLoS One 15:e0234556. 10.1371/journal.pone.0234556.<pub-id pub-id-type="pmid">32555622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0234556</pub-id><pub-id pub-id-type="pmcid">PMC7299392</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandrashekara</surname><given-names>S</given-names></name><name name-style="western"><surname>Shenoy</surname><given-names>P</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>U</given-names></name><name name-style="western"><surname>Pandya</surname><given-names>S</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>A</given-names></name><name name-style="western"><surname>Khare</surname><given-names>A</given-names></name><name name-style="western"><surname>Dudam</surname><given-names>R</given-names></name><name name-style="western"><surname>Goswami</surname><given-names>RP</given-names></name></person-group><article-title>Increase in comorbidities with age among patients with psoriatic arthritis: a multicenter observational study</article-title><source>Rheumatol Int</source><year>2025</year><volume>45</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1007/s00296-024-05760-9</pub-id><pub-id pub-id-type="pmid">39786433</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Chandrashekara S, Shenoy P, Kumar U, Pandya S, Ghosh A, Khare A, Dudam R, Goswami RP (2025) Increase in comorbidities with age among patients with psoriatic arthritis: a multicenter observational study. Rheumatol Int 45:23. 10.1007/s00296-024-05760-9<pub-id pub-id-type="pmid">39786433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00296-024-05760-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solberg</surname><given-names>SM</given-names></name></person-group><article-title>Psoriasis in Norway: a prescription-based registry study of incidence and prevalence</article-title><source>Acta Derm Venereol</source><year>2023</year><volume>103</volume><fpage>adv4591</fpage><pub-id pub-id-type="doi">10.2340/actadv.v103.4591</pub-id><pub-id pub-id-type="pmid">37073961</pub-id><pub-id pub-id-type="pmcid">PMC10128149</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Solberg SM (2023) Psoriasis in Norway: a prescription-based registry study of incidence and prevalence. Acta Derm Venereol 103:adv4591. 10.2340/actadv.v103.4591<pub-id pub-id-type="pmid">37073961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2340/actadv.v103.4591</pub-id><pub-id pub-id-type="pmcid">PMC10128149</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagenstr&#246;m</surname><given-names>K</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>K</given-names></name><name name-style="western"><surname>Garbe</surname><given-names>C</given-names></name><name name-style="western"><surname>Augustin</surname><given-names>M</given-names></name></person-group><article-title>Prevalence of psoriasis and psoriatic arthritis in Germany - analysis of claims data</article-title><source>JDDG J Dtsch Dermatol Ges</source><year>2024</year><volume>22</volume><fpage>45</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1111/ddg.15269</pub-id><pub-id pub-id-type="pmid">38128108</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Hagenstr&#246;m K, M&#252;ller K, Garbe C, Augustin M (2024) Prevalence of psoriasis and psoriatic arthritis in Germany - analysis of claims data. JDDG J Dtsch Dermatol Ges 22:45&#8211;54. 10.1111/ddg.15269<pub-id pub-id-type="pmid">38128108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ddg.15269</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armstrong</surname><given-names>AW</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>MD</given-names></name><name name-style="western"><surname>Schupp</surname><given-names>CW</given-names></name><name name-style="western"><surname>Gondo</surname><given-names>GC</given-names></name><name name-style="western"><surname>Bell</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>CEM</given-names></name></person-group><article-title>Psoriasis prevalence in adults in the United States</article-title><source>JAMA Dermatol</source><year>2021</year><volume>157</volume><fpage>940</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2021.2007</pub-id><pub-id pub-id-type="pmid">34190957</pub-id><pub-id pub-id-type="pmcid">PMC8246333</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM (2021) Psoriasis prevalence in adults in the united States. JAMA Dermatol 157:940&#8211;946. 10.1001/jamadermatol.2021.2007<pub-id pub-id-type="pmid">34190957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamadermatol.2021.2007</pub-id><pub-id pub-id-type="pmcid">PMC8246333</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kubota</surname><given-names>K</given-names></name><name name-style="western"><surname>Kamijima</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sato</surname><given-names>T</given-names></name><name name-style="western"><surname>Ooba</surname><given-names>N</given-names></name><name name-style="western"><surname>Koide</surname><given-names>D</given-names></name><name name-style="western"><surname>Iizuka</surname><given-names>H</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>H</given-names></name></person-group><article-title>Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese National claims database</article-title><source>BMJ Open</source><year>2015</year><volume>5</volume><fpage>e006450</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2014-006450</pub-id><pub-id pub-id-type="pmid">25588781</pub-id><pub-id pub-id-type="pmcid">PMC4298108</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Kubota K, Kamijima Y, Sato T, Ooba N, Koide D, Iizuka H, Nakagawa H (2015) Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese National claims database. BMJ Open 5:e006450. 10.1136/bmjopen-2014-006450<pub-id pub-id-type="pmid">25588781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2014-006450</pub-id><pub-id pub-id-type="pmcid">PMC4298108</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stajszczyk</surname><given-names>M</given-names></name><name name-style="western"><surname>Kwiatkowska</surname><given-names>B</given-names></name><name name-style="western"><surname>&#379;uber</surname><given-names>ZM</given-names></name><name name-style="western"><surname>Batko</surname><given-names>B</given-names></name></person-group><article-title>Access to biologics and JAK inhibitors for the treatment of rheumatic diseases in the biosimilars era in Poland: nation-level study</article-title><source>Pol Arch Intern Med</source><year>2024</year><volume>134</volume><fpage>16655</fpage><pub-id pub-id-type="doi">10.20452/pamw.16655</pub-id><pub-id pub-id-type="pmid">38165391</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Stajszczyk M, Kwiatkowska B, &#379;uber ZM, Batko B (2024) Access to biologics and JAK inhibitors for the treatment of rheumatic diseases in the biosimilars era in Poland: nation-level study. Pol Arch Intern Med 134:16655. 10.20452/pamw.16655<pub-id pub-id-type="pmid">38165391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.20452/pamw.16655</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abel</surname><given-names>ZDV</given-names></name><name name-style="western"><surname>Roope</surname><given-names>LSJ</given-names></name><name name-style="western"><surname>Duch</surname><given-names>R</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>PM</given-names></name></person-group><article-title>Access to healthcare services during the COVID-19 pandemic: a cross-sectional analysis of income and user-access across 16 economically diverse countries</article-title><source>BMC Public Health</source><year>2024</year><volume>24</volume><fpage>2678</fpage><pub-id pub-id-type="doi">10.1186/s12889-024-20147-y</pub-id><pub-id pub-id-type="pmid">39350210</pub-id><pub-id pub-id-type="pmcid">PMC11443786</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Abel ZDV, Roope LSJ, Duch R, Clarke PM (2024) Access to healthcare services during the COVID-19 pandemic: a cross-sectional analysis of income and user-access across 16 economically diverse countries. BMC Public Health 24:2678. 10.1186/s12889-024-20147-y<pub-id pub-id-type="pmid">39350210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12889-024-20147-y</pub-id><pub-id pub-id-type="pmcid">PMC11443786</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krajewska-W&#322;odarczyk</surname><given-names>M</given-names></name><name name-style="western"><surname>Szel&#261;g</surname><given-names>M</given-names></name><name name-style="western"><surname>Batko</surname><given-names>B</given-names></name><name name-style="western"><surname>&#379;uber</surname><given-names>Z</given-names></name><name name-style="western"><surname>Orlea&#324;ski</surname><given-names>M</given-names></name><name name-style="western"><surname>Podw&#243;jcic</surname><given-names>K</given-names></name><name name-style="western"><surname>Sowi&#324;ski</surname><given-names>J</given-names></name><name name-style="western"><surname>Jopek</surname><given-names>J</given-names></name><name name-style="western"><surname>&#346;widerek</surname><given-names>M</given-names></name><name name-style="western"><surname>Maluchnik</surname><given-names>M</given-names></name><name name-style="western"><surname>Brzosko</surname><given-names>M</given-names></name><name name-style="western"><surname>&#346;miglewska</surname><given-names>A</given-names></name><name name-style="western"><surname>Kwiatkowska</surname><given-names>B</given-names></name></person-group><article-title>Rheumatoid arthritis epidemiology: a nationwide study in Poland</article-title><source>Rheumatol Int</source><year>2024</year><volume>44</volume><fpage>1155</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1007/s00296-024-05591-8</pub-id><pub-id pub-id-type="pmid">38678142</pub-id><pub-id pub-id-type="pmcid">PMC11108940</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Krajewska-W&#322;odarczyk M, Szel&#261;g M, Batko B, &#379;uber Z, Orlea&#324;ski M, Podw&#243;jcic K, Sowi&#324;ski J, Jopek J, &#346;widerek M, Maluchnik M, Brzosko M, &#346;miglewska A, Kwiatkowska B (2024) Rheumatoid arthritis epidemiology: a nationwide study in Poland. Rheumatol Int 44:1155&#8211;1163. 10.1007/s00296-024-05591-8<pub-id pub-id-type="pmid">38678142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00296-024-05591-8</pub-id><pub-id pub-id-type="pmcid">PMC11108940</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#379;uber</surname><given-names>Z</given-names></name><name name-style="western"><surname>Podw&#243;jcic</surname><given-names>K</given-names></name><name name-style="western"><surname>Szel&#261;g</surname><given-names>M</given-names></name><name name-style="western"><surname>Krajewska-W&#322;odarczyk</surname><given-names>M</given-names></name><name name-style="western"><surname>Batko</surname><given-names>K</given-names></name><name name-style="western"><surname>Orlea&#324;ski</surname><given-names>M</given-names></name><name name-style="western"><surname>Sowi&#324;ski</surname><given-names>J</given-names></name><name name-style="western"><surname>&#346;widerek</surname><given-names>M</given-names></name><name name-style="western"><surname>&#346;miglewska</surname><given-names>A</given-names></name><name name-style="western"><surname>Maluchnik</surname><given-names>M</given-names></name><name name-style="western"><surname>Brzosko</surname><given-names>M</given-names></name><name name-style="western"><surname>Kwiatkowska</surname><given-names>B</given-names></name><name name-style="western"><surname>Stajszczyk</surname><given-names>M</given-names></name><name name-style="western"><surname>Batko</surname><given-names>B</given-names></name></person-group><article-title>Epidemiology and comorbidity of juvenile idiopathic arthritis in Poland &#8211; a nationwide study</article-title><source>Pediatr Rheumatol</source><year>2025</year><volume>23</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/s12969-025-01065-8</pub-id><pub-id pub-id-type="pmcid">PMC11951515</pub-id><pub-id pub-id-type="pmid">40156029</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">&#379;uber Z, Podw&#243;jcic K, Szel&#261;g M, Krajewska-W&#322;odarczyk M, Batko K, Orlea&#324;ski M, Sowi&#324;ski J, &#346;widerek M, &#346;miglewska A, Maluchnik M, Brzosko M, Kwiatkowska B, Stajszczyk M, Batko B (2025) Epidemiology and comorbidity of juvenile idiopathic arthritis in Poland &#8211; a nationwide study. Pediatr Rheumatol 23:33. 10.1186/s12969-025-01065-8<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12969-025-01065-8</pub-id><pub-id pub-id-type="pmcid">PMC11951515</pub-id><pub-id pub-id-type="pmid">40156029</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>